Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
CND Life Sciences
Study ID
NCT07428447
Status
Recruiting

Conditions

  • Essential Tremor
  • Essential Tremor, Movement Disorders
  • Essential Tremor-plus

Eligibility Criteria

Sex
ALL
Age
50 Years - 85 Years
Healthy Volunteers
Not accepted

Study Details

Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies. Primary Objectives 1. Identify which ET patients have P-SYN pathology indicative of prodromal PD 2. Predict which patients are most likely to phenoconvert to PD

Key Dates

Start date
Feb 18, 2026
Status verified
Feb 2026
Primary completion
Feb 28, 2027
Completion
Feb 28, 2029

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Essential Tremor
    Those diagnosed with Essential Tremor
  • Arm: Essential Tremor Plus
    Those diagnosed with Essential Tremor Plus

Primary Outcome Measure

Quantity of P-SYN in skin [ Time Frame: From enrollment to completion of study participation from Baseline to Month 12 and then to Month 24 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
CND Clinical Research CenterScottsdaleArizona85258
Jeannie Director of Clinical Research
480-434-6446

Find similar trials in Scottsdale, AZ

Related Studies